Loading
A phase 1/2 trial of Tislelizumab in colorectal cancer, run by BeiGene, active and no longer recruiting.
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05609370 by BeiGene, with 113 participants enrolled, started 2023-01-29 and due to reach its primary completion in 2025-05-23. Interventions recorded: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP). Conditions listed: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
113 enrolled.
Values could not be estimated due to an insufficient number of events; Figures from the ClinicalTrials.gov results section (first posted 2026-06-30), not from a publication · 95% CI 2.1 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and Cprimary | Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine | 18 | Values could not be estimated due to an insufficient number of events; Figures from the ClinicalTrials.gov results section (first posted 2026-06-30), not from a publication | 0.37 (0.1 to 1.33) | - | link |
| Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | 16 | 4.4 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares Tislelizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/